Matthew S. Davids discusses the available research guiding the selection of therapy for patients with chronic lymphocytic leukemia at the American Society of Hematology's 67th Annual Meeting.
Catherine S. Diefenbach discusses the lymphoma and CLL highlights at the American Society of Hematology's 67th Annual Meeting.
Video: https://medicaldigest.org/scientific-contents/interview:lymphoma-and-cll-highlights-ash-2025
Rahul Banerjee discusses the quadruplet therapy in multiple myeloma at the American Society of Hematology's 67th Annual Meeting.
Video: https://medicaldigest.org/scientific-contents/interview:quadruplet-therapy-multiple-myeloma
Jennifer Woyach discusses the noncovalent BTK inhibitor pirtobrutinib achieved noninferiority to the covalent BTK inhibitor ibrutinib in terms of overall response rate in patients with CLL or SLL, according to findings from a randomized phase III trial presented at the American Society of Hematology's 67th Annual Meeting.
Anand A. Patel discusses the primary efficacy analysis of a Phase II study investigating tyrosine kinase inhibitor and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukemia at the American Society of Hematology's 67th Annual Meeting.
Jesse Tettero discusses the results from the HARMONY Alliance study at the American Society of Hematology's 67th Annual Meeting.
Jennifer R. Brown explains the results from the ALPINE trial at the American Society of Hematology's 67th Annual Meeting.
Amir Fathi discusses the results from a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia at the American Society of Hematology's 67th Annual Meeting.
Enrique Ocio discusses what's new in multiple myeloma treatement at the American Society of Hematology's 67th Annual Meeting.
Video: https://medicaldigest.org/scientific-contents/interview:whats-new-myeloma
Mark Levis discusses the novelties in acute myeloid leukemia at the American Society of Hematology's 67th Annual Meeting.
Video: https://medicaldigest.org/scientific-contents/interview:novelties-acute-myeloid-leukemia-ash2025
Michael J. Mauro discusses the state of the art treatment of chronic myeloid leukemia at the American Society of Hematology's 67th Annual Meeting.
Video: https://medicaldigest.org/scientific-contents/interview:state-art-treatment-chronic-myeloid-leukemia
Mikkael A. Sekeres discusses the state of the art treatment in myelodysplastic syndrome at the American Society of Hematology's 67th Annual Meeting.
Video: https://medicaldigest.org/scientific-contents/interview:myelodysplastic-syndrome-highlights-ash-2025
Andrzej Jakubowiak discusses the COBRA trial and other novelties in multiple myeloma at the American Society of Hematology's 67th Annual Meeting.
Paul G Richardson discusses multiple myeloma highlights at the American Society of Hematology's 67th Annual Meeting.
Video: https://medicaldigest.org/scientific-contents/interview:multiple-myeloma-highlights-ash-2025
Sigbjorn Berentsen discusses the diagnosis and management of cold agglutinin disease at the American Society of Hematology's 67th Annual Meeting.
Xavier Leleu explains the breakthrough in the treatement of multiple myeloma at the American Society of Hematology's 67th Annual Meeting.
Video: https://medicaldigest.org/scientific-contents/interview:breakthrough-treatement-multiple-myeloma
Joshua Brody discusses the novelties in diffuse large B-cell lymphoma at the American Society of Hematology's 67th Annual Meeting.
Wojciech Jurczak discusses the results from the global, randomized BRUIN CLL-313 study presented at the American Society of Hematology's 67th Annual Meeting.Video: https://medicaldigest.org/scientific-contents/interview:first-its-kind-phase-3-trial-shows-pirtobrutinib-noninferior-ibrutinib-treatment-naive-cll
Sabina Chiaretti discusses the results of the phase 3 GIMEMA ALL2820 study at the American Society of Hematology's 67th Annual Meeting.
Hanny Al-Samkari discusses the results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia who failed first-line corticosteroid treatment at the American Society of Hematology's 67th Annual Meeting.